AN UNBIASED VIEW OF HOW TO USE MOUNJARO

The demo accomplished both equally its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically important and outstanding improvements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH in comparison to placebo.1Fantastic